http://www.aboutlawsuits.com/vytorin-problems-mount-277/ News and Information about Personal Injury Lawsuits Thu, 18 Mar 2010 15:05:41 -0500 http://wordpress.org/?v=2.8.6 hourly 1 http://www.aboutlawsuits.com/vytorin-problems-mount-277/comment-page-1/#comment-1018 Researcher Claims “No Credible Evidence” of Vytorin Cancer Side Effects : AboutLawsuits.com Sun, 21 Sep 2008 03:01:20 +0000 http://www.aboutlawsuits.com/?p=277#comment-1018 [...] emerged about potential Vytorin cancer side effects in July 2008, when data was released from the SEAS study (Simvastatin and Ezetimibe in Aortic [...] [...] emerged about potential Vytorin cancer side effects in July 2008, when data was released from the SEAS study (Simvastatin and Ezetimibe in Aortic [...]

]]> http://www.aboutlawsuits.com/vytorin-problems-mount-277/comment-page-1/#comment-274 FDA Investigating Link between Vytorin and Cancer : AboutLawsuits.com Fri, 22 Aug 2008 15:41:10 +0000 http://www.aboutlawsuits.com/?p=277#comment-274 [...] Warning Issued by FDARhabdomyolysis Lawsuits Vytorin Cancer Risk Dismissed by Drug MakersVytorin Problems Mount as Drug Found to Not Improve Outcomes in Heart Study FDA Highlights Regranex Foot Ulcer Gel Cancer WarningsRegranex LawsuitsFDA Investigates Possible [...] [...] Warning Issued by FDARhabdomyolysis Lawsuits Vytorin Cancer Risk Dismissed by Drug MakersVytorin Problems Mount as Drug Found to Not Improve Outcomes in Heart Study FDA Highlights Regranex Foot Ulcer Gel Cancer WarningsRegranex LawsuitsFDA Investigates Possible [...]

]]> http://www.aboutlawsuits.com/vytorin-problems-mount-277/comment-page-1/#comment-116 Vytorin Cancer Risk Dismissed by Drug Makers — AboutLawsuits.com Thu, 24 Jul 2008 17:33:28 +0000 http://www.aboutlawsuits.com/?p=277#comment-116 [...] in Aortic Stenosis (SEAS) trial, which involved nearly 1,900 patients, showed that Vytorin was no better than a placebo in lowering the risk of heart disease in patients whose heart valves were p.... A similar result was observed in the prevalence of aortic valve disease events, which was the [...] [...] in Aortic Stenosis (SEAS) trial, which involved nearly 1,900 patients, showed that Vytorin was no better than a placebo in lowering the risk of heart disease in patients whose heart valves were p…. A similar result was observed in the prevalence of aortic valve disease events, which was the [...]

]]>